Close Menu

mergers & acquisitions

Illumina's revenues rose sharply on rapid uptake of its HiSeq system. The firm also acquired Helixis for up to $105 million, providing it with a new, low-cost, real-time PCR system for genetic analysis.

The acquisition of the CLIA-certified lab will accelerate development of Iris' NADiA platform.

The deal combines Axela's multiplex protein biomarker testing capabilities and Xceed's Ziplex System for gene expression analysis, with a focus on multiplex diagnostic assays.

Meridian Bioscience's acquisition of Bioline both provides Meridian a foothold in the PCR market and is expected to help drive future diagnostic development at the company.

The deal is expected to bolster Thermo's capabilities in PCR and quantitative real-time PCR.

MDRNA, now known as Marina Biotech, plans a 1-for-4 reverse stock split, which will enable it to have enough authorized shares to consummate the acquisition of Cequent.

Meridian has acquired the reagents maker, adding complementary products to its life science business. The firm also reported an 11 percent decline in Q3 revenues.

The acquisition will add reagents for nucleic acid and protein purification, restriction and modifying enzymes, and other life science research and diagnostic tools to Thermo's Analytical Technologies portfolio.

Merck KGaA has formed a new division, called EMD Millipore, which had pro forma revenues of around $2.9 billion in 2009.

The deal adds to Evotec research funds and potential milestone payments associated with DeveloGen's discovery alliance with Boehringer Ingelheim on small molecules to treat type 2 diabetes.

Pages

Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.

US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.

The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.

In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.